Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03601637
Recruitment Status : Recruiting
First Posted : July 26, 2018
Last Update Posted : September 2, 2019
Sponsor:
Information provided by (Responsible Party):
Vertex Pharmaceuticals Incorporated

Brief Summary:
This study will evaluate the safety and pharmacokinetics (PK) of lumacaftor (LUM) and ivacaftor (IVA) in subjects 1 to less than 2 years of age with cystic fibrosis (CF), homozygous for F508del (F/F).

Condition or disease Intervention/treatment Phase
Cystic Fibrosis Drug: LUM Drug: IVA Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, 2-part, Open-label Study to Evaluate the Safety and Pharmacokinetics of Lumacaftor/Ivacaftor in Subjects 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
Actual Study Start Date : August 23, 2018
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : September 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cystic Fibrosis
Drug Information available for: Ivacaftor

Arm Intervention/treatment
Experimental: Part A Cohort 1 [aged 18 to <24 months]
Subjects will receive LUM/IVA as FDC granules dependent upon weight at Day 1.
Drug: LUM
Fixed Dose Combination (FDC) granule (LUM/IVA)
Other Names:
  • lumacaftor
  • VX-809

Drug: IVA
FDC granule (LUM/IVA)
Other Names:
  • ivacaftor
  • VX-770

Experimental: Part A Cohort 2 [12 to <18months]
Subjects will receive LUM/IVA as FDC granules dependent upon weight at Day 1.
Drug: LUM
Fixed Dose Combination (FDC) granule (LUM/IVA)
Other Names:
  • lumacaftor
  • VX-809

Drug: IVA
FDC granule (LUM/IVA)
Other Names:
  • ivacaftor
  • VX-770

Experimental: Part B
Subjects will receive LUM/IVA as FDC granules dependent upon weight at Day 1.
Drug: LUM
Fixed Dose Combination (FDC) granule (LUM/IVA)
Other Names:
  • lumacaftor
  • VX-809

Drug: IVA
FDC granule (LUM/IVA)
Other Names:
  • ivacaftor
  • VX-770




Primary Outcome Measures :
  1. Part A: Area under the concentration versus time curve during a dosing interval (AUCtau) of LUM and IVA [ Time Frame: from baseline through safety follow-up (up to 10 days after the last dose) ]
  2. Part B: Safety and tolerability as assessed by number of subjects with adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: from baseline through safety follow-up (up to 2 weeks after the last dose) ]

Secondary Outcome Measures :
  1. Part A: Safety and tolerability as assessed by number of subjects with adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: from baseline through safety follow-up (up to 10 days after the last dose) ]
  2. Part A: Average observed pre-dose concentrations (Ctrough) of LUM and IVA metabolites [ Time Frame: from baseline through safety follow-up (up to 10 days after the last dose) ]
  3. Part B: Absolute change in sweat chloride [ Time Frame: from baseline at Week 24 ]
  4. Part B: Average observed pre-dose concentration (Ctrough) of LUM, IVA, and their respective metabolites [ Time Frame: from baseline through safety follow-up (up to 2 weeks after the last dose) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Months to 23 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Subjects will be 1 to less than 2 years of age on Day 1 of the relevant part of the study.
  • Homozygous for F508del (F/F).

Key Exclusion Criteria:

  • Any clinically significant laboratory abnormalities at the Screening Visit that would interfere with the study assessments or pose an undue risk for the subject.
  • Solid organ or hematological transplantation.

Other protocol defined Inclusion/Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03601637


Contacts
Layout table for location contacts
Contact: Medical Information 617-341-6777 medicalinfo@vrtx.com

  Show 23 Study Locations
Sponsors and Collaborators
Vertex Pharmaceuticals Incorporated

Layout table for additonal information
Responsible Party: Vertex Pharmaceuticals Incorporated
ClinicalTrials.gov Identifier: NCT03601637     History of Changes
Other Study ID Numbers: VX16-809-122
2017-004794-13 ( EudraCT Number )
First Posted: July 26, 2018    Key Record Dates
Last Update Posted: September 2, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cystic Fibrosis
Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Ivacaftor
Chloride Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action